



Public Health
England

Protecting and improving the nation's health

Screening Quality Assurance visit report

NHS Cervical Screening Programme
Mid Cheshire Hospitals NHS Foundation
Trust

3 July 2019

About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support.

Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG

Tel: 020 7654 8000 www.gov.uk/phe

Twitter: [@PHE_uk](https://twitter.com/PHE_uk) Facebook: www.facebook.com/PublicHealthEngland

About PHE screening

Screening identifies apparently healthy people who may be at increased risk of a disease or condition, enabling earlier treatment or informed decisions. National population screening programmes are implemented in the NHS on the advice of the UK National Screening Committee (UK NSC), which makes independent, evidence-based recommendations to ministers in the 4 UK countries. PHE advises the government and the NHS so England has safe, high quality screening programmes that reflect the best available evidence and the UK NSC recommendations. PHE also develops standards and provides specific services that help the local NHS implement and run screening services consistently across the country.

www.gov.uk/phe/screening Twitter: [@PHE_Screening](https://twitter.com/PHE_Screening) Blog: phescreening.blog.gov.uk

For queries relating to this document, please contact: phe.screeninghelpdesk@nhs.net



© Crown copyright 2019

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](http://www.ogil.io). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published

PHE publications

gateway number: GW-859

PHE supports the UN

Sustainable Development Goals



Executive summary

The NHS Cervical Screening Programme invites women between the ages of 25 and 64 for regular cervical screening. This aims to detect abnormalities within the cervix that could, if undetected and untreated, develop into cervical cancer.

The findings in this report relate to the quality assurance visit of the Mid Cheshire Hospitals NHS Foundation Trust (MCHT) screening service held on 3 July 2019.

Quality assurance purpose and approach

Quality assurance (QA) aims to maintain national standards and promote continuous improvement in cervical screening. This is to ensure that all eligible people have access to a consistent high quality service wherever they live.

QA visits are carried out by the PHE screening quality assurance service (SQAS).

The evidence for this report comes from:

- routine monitoring data collected by the NHS screening programmes
- data and reports from external organisations
- evidence submitted by the provider(s), commissioner and external organisations
- information shared with the North regional SQAS as part of the visit process

Local screening service

The trust serves a local population of approximately 300,000. There is a eligible cervical screening population of 73,938 women. NHS England and NHS Improvement, Cheshire and Merseyside, has the lead commissioning responsibility for the cervical screening programme at MCHT. Vale Royal Clinical Commissioning Group (CCG) and South Cheshire CCG are the contract holders for colposcopy.

Findings

SQAS last visited MCHT in 2014. Since this visit, they have been proactive in reducing their biopsy rate and auditing their colposcopy service. There are long turnaround times and a significant backlog of cytology samples at the University Hospital of North Midlands cytology service that is impacting upon service delivery at MCHT. Histopathology services provided to MCHT and East Cheshire Hospital Trust are failing to meet the expected turnaround times due to the lack of cervical histopathology reporting staff.

Immediate concerns

The QA visit team identified 4 immediate concerns. A letter was sent to the interim chief executive on 5 July 2019 asking that the trust addresses the following items within 7 days:

- ensure that there is individual patient tray set up within colposcopy clinic and an infection control assessment of the storage of used equipment within the clinical area
- audit the use of provisional pathology reports in liaison with colposcopy (MCHT and East Cheshire NHS Trust) to assess their suitability to support the patient management pathway
- audit the results of histopathology samples that are recorded as not reported by a histopathologist that meets NHSCSP criteria
- ensure that MDT meeting arrangements meet national guidance

A response was received, and actions have been taken to partially mitigate the immediate risks within the programme.

High priority

The QA visit team identified 18 high priority findings. These related to 6 main themes: commissioner oversight, leadership roles, staffing, capacity and recovery planning, colposcopy IT systems, policies and protocols, and multi-disciplinary team (MDT) meetings. Further detail is provided below:

- it is not clear how the Cheshire and Merseyside commissioners will maintain formal oversight of their NHSCSP services if there is any reconfiguration of the strategic programme boards following the laboratory reconfiguration
- the lead histopathologist is not formally appointed to their role with an appropriate job description, sufficient time, and administrative support to carry out the requirements of the role
- not all disciplines are aware to notify the CSPL if an NHSCSP incident occurs
- histology staffing is at a critical level and impacting on their turnaround times (TATs)
- there is no policy to check the suitability of locums to work within the NHSCSP
- colposcopy clinics led by nurse colposcopists are not supported by the required staff
- there is no plan in place to manage the potential increase in colposcopy work following the reduction of the cytology backlog, implementation of HPV Primary Screening and recovery of the histology TATs
- manual intervention is required to produce the mandated colposcopy data returns
- the colposcopy IT system is not available in theatre
- there is no protocol for the use of diathermy equipment
- women who have ablative treatment are followed up in colposcopy whereas women who have excisions are followed up in primary care

- it is not clear that the actual next test due date is being entered on the discharge forms
- not all colposcopists follow national guidance and appropriately discharge women for their test of cure test back into the community
- colposcopy and histopathology attendance at MDT meetings is not in line with national guidance requirements
- the case selection criteria for MDT meetings does not contain all cases required for discussion by national guidance
- the evidence submitted for the visit showed a small number of patient management plans, decided at MDT meetings, which do not follow national guidance

Shared learning

The QA visit team identified several areas of practice for sharing, including:

- engaged CSPL, who is up-to-date with the invasive cancer audit (ICA)
- responsive colposcopy audit schedule following previous visits
- high quality colposcopy guidelines
- consistent completion of patient satisfaction survey with positive patient feedback and action taken on patient suggestions and negative comments
- double clinic slots allocated for women identified with additional needs
- histology department is proactive in training BMSs to complete cut-up

Recommendations

The following recommendations are for the provider to action unless otherwise stated

Governance and leadership

No.	Recommendation	Reference	Timescale	Priority	Evidence required
1	The commissioners should ensure that they maintain formal oversight of their NHSCSP service providers following any reconfiguration of the strategic programme board, aligned with laboratory mobilisation	Public Health Section 7A – Commissioning Intentions 2018 and 2019 NHS Public Health Functions Agreement 2018 to 2019	12 months	High	Terms of reference for programme boards following laboratory’s mobilisation
2	The commissioners should develop an action plan to reduce screening inequalities in underserved and protected population groups	NHS Public Health Functions Agreement 2018 to 2019 Guidance for NHS commissioners on equality and health inequalities legal duties 2015 Service Specification 25	6 months	Standard	Action plan presented to programme board
3	The commissioner should clarify formal links with Styal prison for NHSCSP	Service Specification 25	3 months	Standard	Governance structure and SOP

No.	Recommendation	Reference	Timescale	Priority	Evidence required
4	Ensure that the CSPL has an agreed job description that includes accountability to the CEO and dedicated time in their job plan	NHS Cervical Screening Programme: the role of the cervical screening provider lead	6 months	Standard	CSPL's job description and agreed job plan
5	Produce an annual performance report and 6-monthly update to cover all NHSCSP services provided for the organisation's main clinical governance committee	NHS Cervical Screening Programme: the role of the cervical screening provider lead	12 months	Standard	CSPL report and evidence of presentation at the organisation's main clinical governance committee
6	Develop and implement a whole trust annual audit schedule for cervical screening services	Service Specification 25	3 months	Standard	Annual audit schedule covering colposcopy and histopathology
7	Update the protocol for the completion of the invasive cervical cancer audit (ICA)	NHSCSP 28	6 months	Standard	Updated ratified protocol
8	Update the protocol for failsafe procedures in line with national guidance	Cervical screening: cytology reporting failsafe	6 months	Standard	SOP
9	Ensure sign up to NHSCSP confidentiality and disclosure policy	Service Specification 25	3 months	Standard	Confirmation from the CSPL
10	Update relevant local policies to include reference to managing screening incidents in accordance with "Managing Safety Incidents in NHS Screening Programmes", the current SIAF, and up to date terminology	Managing Safety Incidents in NHS Screening Programmes	3 months	Standard	Updated policies

No.	Recommendation	Reference	Timescale	Priority	Evidence required
11	Ensure CSPL is notified of all NHSCSP incidents	Managing Safety Incidents in NHS Screening Programmes NHS Cervical Screening Programme: the role of the cervical screening provider lead	3 months	High	Incident management flowchart and confirmation of implementation from CSPL
12	Ensure that a lead histopathologist for the NHSCSP is formally appointed with responsibilities included within their job description, dedicated time in their job plan and administrative support	Service Specification 25	3 months	High	Job description, job plan with dedicated professional activity allocation
13	Ensure that there is a mechanism for histopathology to inform the CSPL of all new Invasive Cancer Audit (ICA) cases	NHSCSP 28	3 months	Standard	ICA case management flowchart and confirmation of implementation from CSPL
14	Ensure that the lead nurse colposcopist for the NHSCSP is formally appointed with responsibilities included within their job description, dedicated time in their job plan and administrative support	Service Specification 25	6 months	Standard	Job description, job plan with dedicated professional activity allocation

Diagnosis - histology

No.	Recommendation	Reference	Timescale	Priority	Evidence required
15	Seek support from the pathology network to manage the critical level of pathology staffing	Service Specification 25	3 months	High	Confirmation by lead histopathologist
16	Audit the results of histopathology samples that are recorded as not reported by a histopathologist that meets NHSCSP criteria	RCPATH Service Specification 25	3 months	Immediate	Audit
17	Ensure that local policy is followed for all NHSCSP samples stating that all NHSCSP samples are to be reported by a histopathologist that meets the requirements of the NHSCSP or sent to the outsourcing agency	RCPATH Service Specification 25	3 months	Standard	Workload data for individuals reporting NHSCSP specimens
18	Ensure that there is a policy in place to check the suitability of locums, including non-consultant staff, to work within the NHSCSP	RCPATH NHS employers guidance on the appointment and employment of doctors	6 months	High	Ratified policy with evidence of implementation
19	Ensure that histopathologists have access to cervical screening results	RCPATH	6 months	Standard	Arrangements for accessing cervical screening results in place

No.	Recommendation	Reference	Timescale	Priority	Evidence required
20	Audit the use of provisional reports in liaison with colposcopy (MCHT and ECHT) to assess if they support the patient management pathway	RCPATH	3 months	Immediate	Audit
21	Implement a sustainable plan for the delivery of NHSCSP turnaround times (TATs) for histopathology samples	RCPATH Service Specification 25	6 months	High	Plan and update on histology TATs

Intervention and outcome - colposcopy

No.	Recommendation	Reference	Timescale	Priority	Evidence required
22	Ensure that the nurse colposcopists have nursing support in line with NHSCSP 20	NHSCSP 20	3 months	High	Confirmation from lead nurse colposcopist
23	Develop a sustainable plan to manage colposcopy and administration capacity	NHSCSP 20	6 months	High	Plan and update from lead colposcopist
24	Update the induction protocol to be specific to colposcopy	NHSCSP 20	3 months	Standard	Updated protocol
25	Ensure the colposcopy IT system can produce reliable data for KC65 submission and key performance indicators outlined in National Service Specification 25 that is not dependent on manual intervention	Service Specification 25	6 months	High	Audit of KC65 and KPIs

No.	Recommendation	Reference	Timescale	Priority	Evidence required
26	Ensure that there is access to the colposcopy database in theatre	Service Specification 25	6 months	High	Confirmation from lead colposcopist
27	Update the local Trust colposcopy clinical guidelines to ensure terminology is up to date	NHSCSP 20	6 months	Standard	Ratified guidelines
28	Update the colposcopy administration protocols to ensure that they are in line with current practice and contain sufficient information to support cross-cover arrangements	Service Specification 25	6 months	Standard	Administrative protocols
29	Implement SOPs to ensure that colposcopy nurse support staff can manage clinic set up without additional support	NHSCSP 20	6 months	Standard	SOPs
30	Document the protocol for the use of diathermy equipment	NHSCSP 20	3 months	High	Protocol
31	Standardise the management of women treated by ablation rather than excision and their eligibility for primary care follow up in line with NHSCSP 20	NHSCSP 20	3 months	High	Updated colposcopy guidelines and update from lead colposcopist
32	Ensure that individual colposcopists manage their own results to support assessment of individual colposcopy practice and minimise administrative the burden on colposcopy nursing staff	NHSCSP 20	3 months	Standard	Confirmation from lead colposcopist

No.	Recommendation	Reference	Timescale	Priority	Evidence required
33	Complete a retrospective audit to check that the discharge notification process to call/recall has the 'next test due date' correctly completed	NHSCSP 20	6 months	High	Audit
34	Audit HPV triage and test of cure pathway to ensure individual colposcopist compliance and standardise protocols	NHSCSP 20	6 months	High	Audit
35	Audit the number of new appointments compared with the number of follow up appointments in line with NHSCSP 20 to identify actions to manage colposcopy capacity post implementation of HPV primary screening	NHSCSP 20	6 months	Standard	Audit
36	Review all letters and information leaflets to update terminology and to ensure that they are in line with NHSCSP 20	NHSCSP 27 NHSCSP 20	6 months	Standard	Updated letters and leaflets
37	The trust's infection control team should risk assess the current process for non-specific tray set up, which is used for multiple patients within the colposcopy clinics and the of storage of used equipment within the clinical area	NHSCSP 20	3 months	Immediate	Risk assessment with action taken

No.	Recommendation	Reference	Timescale	Priority	Evidence required
38	Review the accessibility of equipment for the completion of cervical screening sampling for women with physical disabilities	Service Specification 25	6 months	Standard	Update from lead colposcopist

Multidisciplinary team

No.	Recommendation	Reference	Timescale	Priority	Evidence required
39	Ensure all colposcopists attend a minimum of 50% of MDT meetings	NHSCSP 20	12 months	High	Attendance record for the 12-month period
40	Ensure histopathology representation at 100% of MDT meetings at both MCHT and East Cheshire NHS Trust	NHSCSP 20	12 months	High	Attendance record for the 12-month period
41	Ensure that MDT meeting arrangements meet national guidance, in terms of slide review by a competent histopathologist, the consistent decision making, and monitoring of the progress of actions	NHSCSP 20 National Service specification 25	6 months	Immediate	SOP
42	Update the case selection criteria for the MDT meetings in line with NHSCSP 20	NHSCSP 20 National Service specification 25	3 months	High	SOP
43	Audit the MDT outcomes to demonstrate consistency in decision making	NHSCSP 20	6 months	High	Audit

Next steps

The screening service provider is responsible for developing an action plan in collaboration with the commissioners to complete the recommendations contained within this report.

The SQAS will make an unannounced visit to the MDT meetings within the next 12 months.

SQAS will work with commissioners to monitor activity and progress in response to the recommendations made for a period of 12 months after the report is published. After this point SQAS will send a letter to the provider and the commissioners summarising the progress made and will outline any further action(s) needed.